Table 3.

Descriptive statistics of noncompartmental pharmacokinetic variables of bivatuzumab mertansine after a 3-week once weekly infusion regimen (n = 7, weeks 1 and 2; n = 6, week 3)

WeekAUC0-168* [(μg · h/mL)/(mg/m2)]Cmax* [(μg/mL)/(mg/m2)]tmax [h]t1/2 [h]CLss [mL/min]Vss [L]
1gMean19.90.5680.7542.1
gCV (%)16.313.20.75-2.084.45
2gMean20.20.5640.78340.2
gCV (%)14.516.40.667-2.1726.5
3gMean20.40.5590.87569.11.515.25
gCV (%)18.917.80.75-2.7514.721.515.0
  • Abbreviations: gMean, geometric mean; gCV, geometric coefficient of variation.

  • * Dose normalized.

  • Median and range.

  • Variables at steady-state.